

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

# Index

- Abramowitz, J.S., 76
- absence seizures, 134–5
- accepting responsibility coping style, 24*t*
- acetylcholine, 65
- ACTH-dependent Cushing's syndrome, 186
- Activate-Initiate-Monitor intervention, 113
- acuteness level, 3
- adaptive coping, 24
- Addison's disease, 187
- adjustment disorder, 235, 238
- adolescents. *See* children
- adrenal disorders, 186–7
- adrenocorticotrophic hormone (ACTH), 186, 187
- advice, conflicting, 20
- African Americans, renal failure among, 174
- agitation of delirium, 61
- AIDS
- background, 165–6
  - clinical decision-making and treatment
    - overview, 170–1
    - psychopharmacology, 171, 172
    - treatment issues, 171
  - consult question, 163–5
  - how AIDS differs from other medical illnesses, 167*t*
  - work-up, 166–70
- AIDSism, 165–6
- albumin, 37, 178–9
- alcohol and other substance withdrawal issues, 5
- alcohol withdrawal delirium, 6
  - background, 193–4, 196–7
  - clinical decision-making and treatment, 195–6
  - accelerated methods, 200
  - opioid agonist therapy, 197–8, 199
  - pregnancy, 200
  - symptomatic detoxification, 199–200
  - consult question, 193
  - fixed schedule regimens for, 196*t*
  - opioid withdrawal, 196
  - sedative/hypnotic withdrawal, 196
  - treatment with valproic acid, 39
  - work-up, 194–5, 197
- alcohol dependence, and renal failure, 177
- alprazolam, 33*t*
- Alzheimer's disease (AD), 89, 90–1
- American Psychiatric Associations (APA), 52
- American Society of Addiction Medicine, 195
- American Society of Clinical Oncology, 149
- amiodarone, 38*t*
- amitriptyline, 33*t*
- analgesia, 198
- Andersen, G., 111*t*
- anhedonic depression, 238
- anorexia nervosa, 189
- antenatal depression. *See* pregnancy, depression and
- anticholinergic medications, 11, 213
- anticonvulsants, 39–40
- for agitation in dementia, 95
  - carbamazepine, 40
  - for dementia and agitation, 95
  - gabapentin, 39
  - lamotrigine, 40
  - overview, 39
  - oxcarbazepine, 40
  - pregabalin, 39
  - topiramate, 40
  - valproic acid, 39–40
- antidepressants, 41–4. *See also*
- selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine reuptake inhibitors (SNRIs); tricyclic antidepressants (TCAs)
  - for agitation in dementia, 96
  - atypical, 43–4
  - for cancer patients
  - for children, 254, 255*t*
  - for dementia and agitation, 96
  - for depressed patients with heart disease, 104, 104*t*, 104
  - for end-stage renal disease (ESRD), 178, 180*t*, 179–81
  - for hypothyroidism, 190
  - for infants of breastfeeding mothers, 205
  - for interferon-induced depression, 158–9
  - lactation and, 205
  - MAOIs, 41–2
  - for organ transplant patients, 213
  - overview, 41
  - for patients in treatment for HCV, 155
  - for people with epilepsy (PWE), 139
  - for perinatal depression, 204–5

## Index

- antidepressants (*cont.*)  
   for poststroke depression, 107–9, 110, 112  
   mortality, 112  
   recovery in activities of daily living, 112  
   recovery in cognitive function, 112  
   QTc and, 5–6  
   for renal failure and depression, 179–81
- antiemetics, 117
- antiepileptic drugs (AEDs)  
   recommendations by seizure type and patient group, 138*t*  
   risk factors, 138–9  
   whether role in cognitive and psychiatric symptoms, 137–8
- antifungals, 38*t*
- antipsychotics, 45–6, 48  
   for agitation in dementia, 94–5  
   atypical/second generation, 47–8  
   for children, 254, 255*t*  
   cited problems with, 30  
   conventional/first generation, 47  
   for dementia and agitation, 94–5  
   for Parkinson's disease, 117, 121  
   for people with epilepsy (PWE), 139, 140  
   for pregnancy and depression, 205–6  
   QTc and, 5–6
- antisocial personality disorder (ASPD), 86  
   in self-destructive deniers, 29  
   as suicide risk factor, 52
- anxiety, 120  
   in cancer patients, 143  
   cognitive-behavioral therapy (CBT) for, 245  
   and demoralization, 239–40  
   following traumatic brain injury  
   in hepatitis C patients, 154  
   in hyperparathyroidism, 186  
   in organ transplant patients, 213, 214  
   in Parkinson's disease patients, 120  
   in people with epilepsy (PWE), 135, 136  
   in terminally ill patients, 226, 231*t*
- anxiolytics, 44–5. *See also* benzodiazepines  
   buspirone, 45  
   for children, 255*t*  
   and interferon-induced depression, 158*t*  
   non-benzodiazepine sedative/hypnotic medications, 45  
   for organ transplant patients, 213
- apathetic hyperthyroidism, 185
- apathy  
   in hyperparathyroidism patients, 186  
   in Parkinson's disease patients, 119
- appetite, psychostimulants and, 48. *See also* bariatric surgery; eating disorders; weight problems
- aripiprazole, 33*t*, 191
- art therapy, 11
- Asher, R., 82
- asthma, in children, 249
- Astrom, M., 107
- attention tests, 66
- atypical antidepressants, 43–4
- atypical antipsychotic agents, 47–8, 139
- barbiturates, 196
- bariatric surgery  
   background, 216–19  
   consult question, 216  
   contraindications to, 221  
   work-up  
     adherence, 222  
     overview, 219–21  
     psychometric evaluation, 221–2
- Barrett, C.L., 17
- baseline suicide risk category, 55
- Bass, C., 83
- Bean, W. H.
- Beck, A. T., 245
- Beck Anxiety Inventory (BAI-II), 243
- Beck Depression Inventory (BDI), 155, 222
- Beck Depression Inventory (BDI-II), 243
- bedside cognitive testing, 7
- benzodiazepines, 11, 33*t*, 44  
   for alcohol withdrawal, 196  
   for anxiety in Parkinson's disease, 121  
   for interferon-induced depression, 160  
   for people with epilepsy (PWE), 139, 140  
   and personality disorder patients, 61  
   for terminally ill patients, 230–2  
   withdrawal from, 5, 6
- beta-adrenergic receptor stimulants, 228
- beta-blockers  
   for agitation in Huntington's disease (HD), 96  
   for depression in CVD, 105
- binge eating disorder (BED), 218
- biotransformation, 37
- bipolar disorders  
   and hypothyroidism, 191  
   in people with epilepsy (PWE), 136, 139  
   and post-partum depression, 203  
   in terminally ill patients, 226  
   and weight problems, 188
- blood alcohol concentration (BAC), 193–4
- blood pressure, of diabetes patients, 188

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- body dysmorphic disorder (BDD), 77–8  
background, 77  
clinical decision-making and treatment, 77–8  
work-up, 77
- body language, 56, 60
- Body-Esteem Scale for Adolescents and Adults (BESAA), 217
- borderline personality disorder (BPD)  
in manipulative help-rejecters, 28  
as suicide risk factor, 52
- Boston Interview for Gastric Bypass, 220
- Bostwick, J.M., 52
- Braddock, A.E., 76
- bradykinesia, 119
- brain injury. *See* traumatic brain injury (TBI)
- Brief Symptom Inventory, 243
- bromocriptine, 189–90
- bronchodilators, 228
- Bryan, C.J., 52–4
- bulimia nervosa, 189
- buprenorphine, 196, 197, 198, 199*t*, 199
- bupropion, 33*t*  
for AIDS patients, 172  
for depression, 44  
for end-stage renal disease (ESRD) patients, 180*t*, 180, 180*t*, 180  
interaction with medications for CVD, 104*t*  
for interferon-induced depression, 158  
for Parkinson's disease patients  
for people with epilepsy (PWE),  
contraindications, 139  
for perinatal depression, 205  
for traumatic brain injury patients,  
contraindications, 131
- burnout, in cancer professionals, 149
- buspirone, 33*t*, 45, 131
- cabergoline, 189–90
- caffeine, 38*t*
- CAGE questionnaire, 194–5
- calcium  
and hyperparathyroidism, 186  
and hypoparathyroidism, 186
- CAN IT mnemonic, 58–9
- cancer  
in children, 249  
depression and  
background, 143–4  
care for caregivers, 148–9  
consult question, 143  
non-pharmacological therapies for  
pharmacological treatments for, 146–7  
physical symptom burden and distress, 146  
screening for, 144  
survivorship, 149  
methylphenidate treatment, 48
- capacity, assessing in medically ill, 15–20  
background, 15–18  
legal issues, 17–18  
maladaptive denial, 18  
misconceptions, 16–17  
overview, 15–16  
reasons for evaluation, 17  
clinical decision-making and treatment, 19–20  
consult question, 15  
work-up, 18–19
- carbamazepine, 33*t*, 40  
for people with epilepsy (PWE), 139, 140  
for perinatal psychosis patients, 205  
risk factors, 138  
for seizure disorder patients, 135, 137
- carbonic anhydrase inhibitors, 41
- cardiovascular disease (CVD). *See* heart disease
- caregivers, 148–9. *See also* family support
- chaplains, 11
- Chapman, J.S., 82–3
- Charcot, J.-M., 74, 75
- children, chronically ill,  
assessing understanding of illness, 252–3  
asthma in, 249  
background, 249–51  
cancer in, 249  
clinical decision-making and treatment  
overview, 254–6  
transition from pediatric to adult care, 256–7  
consult question, 249  
delayed develop of, 252  
delirium in, 249–50  
developmental stages in, 253*t*  
effect of hospital environment, 252  
factors determining child's response to illness, 250*t*  
family support for, 253–4  
important skills in working with, 252*t*  
major developmental trajectories, 252*t*  
psychiatric symptoms in, 254–6  
psychotropic medications with FDA-approved uses in, 255*t*  
terminal illness and death of, 250  
vulnerable child syndrome, 251*t*  
work-up, 251–4
- children, of women with postpartum depression, 203
- chloral hydrate, 33*t*
- chlordiazepoxide, 33*t*, 196*t*
- chlorpromazine, 47, 139, 232
- Choi-Kwon, S., 111*t*

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- cholinesterase inhibitors
  - for agitation in dementia, 96
  - for Parkinson's disease patients, 122
- chronic high risk category, 55
- chronic high risk with acute exacerbation category, 55
- Chronological Assessment of Suicide Events (CASE Approach), 52
- ciprofloxacin, 38*t*
- citalopram, 33*t*
  - for AIDS patients, 172
  - for cancer patients, 147
  - for depressed patients with heart disease, 102
  - for end-stage renal disease (ESRD) patients, 180*t*
  - for infants of breastfeeding mothers, 205
  - for interferon-induced depression, 158
  - for people with epilepsy (PWE), 139
  - for post-stroke depression, 110
  - for terminally ill patients, 230
  - for traumatic brain injury patients, 131
- Clark, L., 238
- Clinical Global Impression of Change (CGIC), 95
- Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar), 195*t*, 195*t*, 195–6
- Clinical Opiate Withdrawal Scale (COWS), 198
- clomipramine, 33*t*, 139
- clonazepam, 33*t*
  - for AIDS patients, 172
  - for REM behavior disorder (RBD)
- clonidine, 199*t*, 199–200
- close-ended questions, 54
- clozapine, 48
  - for dementia and agitation, 95
  - for Parkinson's disease patients, 121
  - for people with epilepsy (PWE), 139
  - for traumatic brain injury patients,
    - contraindications, 131
    - and weight gain, 188
- cluster B personality disorders, 25, 29
- Cogentin, 61
- cognitive-behavioral therapy (CBT)
  - for cancer patients, 147
  - for depressed patients with heart disease, 103
  - for diabetes patients, 191
  - for end-stage renal disease (ESRD) patients, 181
  - for hospitalized patients, 243–6
  - for hypochondriasis, 76–7
  - for perinatal depression, 204
  - for post-stroke depression, 112
  - for somatization disorder, 74
- cognitive disorders, 121–2, 136
- Cognitive Triad, 245
- Cohen, M.A., 165
- Cohen-Mansfield, J., 89, 94
- cold-deceitful personality type, 24*t*
- collateral information, 8–9
- coma, in hyperparathyroidism, 186
- combination antiretroviral therapy (CART), 165, 166–8
- communication with consulting team, 12
- competency, 3, 16
- competency/capacity interview, 19, 20
- complex partial seizures, 134
- conflicting advice, 20
- confrontations with patients, 26, 28
- confrontative coping style, 24*t*
- Confusion Assessment Method (CAM), 67
- consciousness, assessing, 66
- constipation, in end-stage renal disease (ESRD), 178
- consult question, 3
  - AIDS, 163–5
  - alcohol and other substance withdrawal issues, 193
  - bariatric surgery, 216
  - capacity, assessing in medically ill, 15
  - children, 249
  - dementia, agitation in, 89
  - demoralization, 235
  - depression
    - cancer and, 143
    - heart disease and, 100
    - hepatitis C and, 153
    - post-stroke, 107
    - pregnancy and, 202
    - renal failure and, 174
  - difficult patient encounter, 22
  - end of life, psychiatric care at, 226
  - endocrine and metabolic diseases, 184
  - factitious disorder, 82
  - hospitalized medically ill patient, 242
  - malingerer, 82
  - organ transplantation, 210
  - Parkinson's disease, 116
  - seizure disorders, 134
  - somatoform disorder, 73
  - suicide risk assessment, 51
  - traumatic brain injury, 126
  - violent patients, 58
- consultation note, 10*t*
- consultation process, 1–12
  - acuteness level, 3
  - consult question, 3
  - consulting individual, 1
  - delirium, 64
  - examining patients, 8
  - gathering collateral information, 8–9
  - institutional and personal organization, 1

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- interventions, 9–12
  - ancillary resources, 11
  - communicating directly with consulting team, 12
  - laboratory studies, 11
  - non-pharmacologic interventions, 11
  - notes, 9
  - offering treatment recommendations, 9
  - pharmacologic interventions, 11
  - returning for follow-up visits and recommendations, 12
  - safety, 9–11
- interviewing patients, 6
- notes, 4
- overview, 1, 4
- patient identity and location, 2
- recent orders, 5
- reviewing documentation and results, 4, 5–6
- special cases, 8
- vital signs, 5
- containment of violent patient, 59
- conventional/first generation antipsychotics, 47
- conversion disorder, 74–6
  - background, 74–5
  - clinical decision-making and treatment, 75–6
  - work-up, 75
- coping styles, 23–4, 24*t*, 24
- cortical dementias, 90*t*, 90–1
  - Alzheimer's disease, 90–1
  - fronto-temporal dementia, 91
  - Lewy Body dementia, 91
- corticosteroids, 228
- countertransference, 24*t*, 26
- crisis plan, suicide, 56
- Cushing's syndrome, 186–7, 191
- cyclosporine
  - drug-drug interactions, 38*t*
  - for organ transplant patients, 214
- CYP3A4 inhibitors, 199
- CYP isoenzyme inducers, 140
- CYP2D6 inhibitors, 147
- CYP3A4 inducers, 199
- CYP450 isoenzymes, 37
- cytochrome P450 3A4 inducers, 172
- cytomegalovirus (CMV)
  - retinitis, 163, 166–7
- deep brain stimulation (DBS), 117
- defense mechanisms, 25*t*, 25–6
- deferring consults, 3
- delirium, 6, 64–70, 122
  - in AIDS patients, 169*t*
  - assessment, 65–8
  - background, 64–5
  - in children, 249–50
  - clinical decision-making and treatment, 68–70
  - consultation questions, 64
  - effect on decisions regarding treatment, 20
  - I WATCH DEATH mnemonic, 67*t*
  - laboratory evaluation of, 68*t*
  - life-threatening causes of, 67*t*
  - in organ transplant patients, 213, 214
  - risk factors, 65*t*
  - in terminally ill patients, 227, 230, 231*t*, 232
  - work-up, 65–8
- Delirium Rating Scale, 67
- delirium tremens (DTs), 194
- dementia
  - in AIDS patients, 163–4, 167–8
  - cortical vs. subcortical, 90*t*
  - versus delirium, 65
  - vascular, 91
- dementia, agitation in, 89–96
  - background, 89–92
  - cortical dementias, 90–1
  - mixed dementias, 91
  - overview, 89–90
  - subcortical dementias, 91
  - traumatic brain injury, 92
- clinical decision-making and treatment, 93–6
  - medications for, 94–6
  - overview, 93–4
- consult question, 89
- work-up, 92–3
  - history, 92–3
  - overview, 92
- demoralization
  - background, 235–7
  - case discussion, 240–1
  - clinical decision-making and treatment, 239–40
  - consult question, 235
  - work-up, 237–8
- dependent clingers, 27
- depression
  - cancer and
    - background, 143–4
    - care for caregivers, 148–9
  - consult question, 143
  - non-pharmacological therapies for pharmacological treatments for, 146–7
  - physical symptom burden and distress, 146
  - screening for, 144
  - survivorship, 149
  - effect on decisions regarding treatment, 20
- heart disease and, 100–5
  - background, 100–1
  - clinical decision-making and treatment, 102–5
  - consult question, 100
  - screening and assessment, 102
  - work-up, 102
- hepatitis C and
  - background, 153–5
  - clinical decision-making and treatment
  - consult question, 153
  - future directions, 160
  - guidelines for treatment of IFN, 159*t*
  - medications used for treatment of neuropsychiatric complications of IFN, 158*t*

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- depression (*cont.*)  
 overview, 153  
 proposed mechanisms for  
 interferon-induced  
 depression, 156*t*  
 reasons for psychiatric  
 consultation prior to  
 therapy, 154*t*  
 screening and assessment,  
 155  
 Parkinson's disease and, 119  
 post-stroke, 107–13  
 background, 107–9  
 clinical decision making  
 and treatment of  
 post-stroke depression,  
 109–11  
 consult question, 107  
 effect of antidepressants  
 on outcome, 112  
 preventive intervention,  
 113  
 psychosocial  
 interventions, 112–13  
 work-up, 109  
 pregnancy and  
 background  
 clinical decision-making  
 and treatment  
 consult question, 202  
 work-up, 203  
 renal failure and  
 antidepressant medication  
 therapy, 179–81  
 background  
 clinical decision-making  
 and treatment  
 consult question, 174  
 work-up  
 suicide risk factor, 52  
 traumatic brain injury and  
 background  
 clinical decision-making  
 and treatment  
 consult question, 126  
 work-up, 128–30
- desipramine, 33*t*  
 desvenlafaxine, 33*t*  
 for depression, 42  
 for end-stage renal disease  
 (ESRD) patients, 180*t*  
 detoxification. *See* alcohol and  
 other substance  
 withdrawal issues
- dextroamphetamine, 48,  
 131  
 diabetes mellitus, 187–9  
 diagnostic clarity,  
 psychopharmacology,  
 32  
 dialysis, 175, 176, 177, 178  
 diazepam, 33*t*, 44, 196*t*  
 Dieperink, E., 155  
 differential diagnosis, suicide,  
 58*t*  
 diltiazem, 38*t*  
 Dinwiddie, S.H., 154  
 disordered personality traits,  
 136  
 distancing coping style, 24*t*  
 distant-aloof personality type,  
 24*t*  
 distress  
 in cancer patients, 144, 145*f*,  
 146  
 in family members of cancer  
 patients, 149  
 divalproex sodium, 39  
 doctor- vs. patient-centered  
 approach, 26  
 documentation, 4  
 donepezil, 96  
 Donovan, K.A., 146  
 dopamine, 65  
 and hyperprolactinemia,  
 189  
 treating delirium with, 68  
 dopamine agonists, 158*t*  
 dopamine transporter (DAT),  
 48  
 dopaminergic medications,  
 abuse of, 123–4  
 doxepin, 33*t*, 78  
 dramatizing-emotional  
 personality type, 24*t*  
 droperidol  
 black box warning, 62  
 controlling agitated, 60–1  
 drug absorption, 37  
 drug dependence. *See* alcohol  
 and other substance  
 withdrawal issues;  
 substance abuse  
 drug information pharmacists,  
 32  
 drug-binding proteins, 37  
 drug-drug interactions, 38*t*  
 duloxetine, 33*t*  
 for depressed patients with  
 heart disease, 103  
 for depression, 42–3  
 for end-stage renal disease  
 (ESRD) patients,  
 180*t*  
 for somatization disorder,  
 74  
 dying patients. *See* end of life,  
 psychiatric care at
- eating disorders, 188–9, 191.  
*See also* appetite,  
 psychostimulants and;  
 bariatric surgery;  
 weight problems
- Ebstein's anomaly, 206  
 Edinburgh Postnatal  
 Depression Scale  
 (EPDS), 203  
 electrocardiograms  
 (ECGs/EKGs), 5  
 obtaining prior to  
 droperidol use, 62  
 results of, 5–6  
 electroconvulsive therapy  
 (ECT)  
 for end-stage renal disease  
 (ESRD), 181  
 for Parkinson's disease,  
 120  
 for post-stroke depression,  
 111  
 for traumatic brain injury  
 patients, 131  
 electroencephalogram (EEG),  
 5–6, 68  
 emergent consults, 3  
 emotion-focused coping, 23  
 empathy, 29



Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- end of life, psychiatric care at  
background, 226–8  
clinical decision-making and  
treatment, 230–3  
consult question, 226  
risk factors for depression in  
palliative care patients,  
229*t*  
work-up, 228–30
- endocrine and metabolic  
diseases  
background  
adrenal disorders, 186–7  
diabetes mellitus, 187–9  
hyperparathyroidism, 186  
hyperprolactinemia,  
189–90  
hyperthyroidism, 185  
hypocortisolism, 187  
hypoparathyroidism, 186  
hypothyroidism, 184–5  
overview, 184  
clinical decision-making and  
treatment, 190–1  
consult question, 184  
work-up, 190
- end-stage renal disease  
(ESRD). *See* renal  
failure
- Engel, G., 236
- entitled demanders, 27–8
- environmentally influenced  
traits, 23
- epilepsy, 136–7, 138–9. *See also*  
seizure disorders
- erythromycin, 38*t*
- escape-avoidance coping style,  
24*t*
- escitalopram, 33*t*  
for depressed patients with  
heart disease, 102  
for end-stage renal disease  
(ESRD) patients, 180*t*  
for people with epilepsy  
(PWE), 139
- eszopiclone, 33*t*, 45
- euphoria, 187
- evaluations  
competency/capacity, 19, 20  
PT/OT, 6
- exercise  
for cancer and depression,  
148  
for end-stage renal disease  
(ESRD) patients,  
181  
for major depression in  
CVD, 105  
for people with epilepsy  
(PWE), 139
- existential care, for cancer and  
depression, 148
- factitious disorder, 82–8  
background, 82–5  
clinical decision-making and  
treatment, 86–8  
consult question, 82  
work-up, 85
- false assurances, 236
- family support  
for cancer patients, 148–9  
for children, chronically ill,  
253–4  
for factitious disorder  
patients, 87  
for people with epilepsy  
(PWE), 137  
for traumatic brain injury  
patients, 130, 131
- fasting plasma glucose (FPG),  
188
- fatigue  
cancer-related, 230  
in hyperparathyroidism  
patients, 186  
in interferon-induced  
depression patients, 159
- in Parkinson's disease  
patients, 118
- fear  
effect on decision making  
ability, 20  
importance of  
acknowledging, 58
- Feldman, M., 83, 87
- fentanyl, 69
- Fernandez, F., 165
- fluoxetine, 33*t*
- for infants of breastfeeding  
mothers, 205  
interaction with medications  
for CVD, 104*t*, 104  
for people with epilepsy  
(PWE), 140  
for poststroke depression,  
110  
for traumatic brain injury  
patients, 131
- fluvoxamine, 33*t*  
interaction with medications  
for CVD, 104*t*, 104,  
104*t*, 104  
for people with epilepsy  
(PWE), 140
- Fobi, M.A.I., 216
- folic acid supplementation, 148
- follow-up visits, 12
- Folstein Mini Mental State  
Examination (MMSE),  
66–7, 92
- Frank, Jerome, 236
- Freud, Sd
- fronto-temporal dementia  
(FTD), 91
- Fruehwald, S., 111*t*
- gabapentin, 33*t*, 39, 40, 140
- gamma-aminobutyric acid  
(GABA), 39, 44
- gastric absorption, drugs, 37
- gastric banding, 218, 219
- gastroplasty, 218
- gate questions, 54
- general delirium, 6
- general seizures, 134–5
- gentle assumption, suicide risk  
assessment, 54–5
- “The Giving Up – Given Up  
Complex” (Engel), 236
- Glasgow Coma Scale, 66*t*, 66,  
66*t*, 66
- globulin, 37
- glomerular filtration rate  
(GFR), 41

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- glucocorticoid production, 187
- Gorman, J.M., 165
- Grade, C., 111*t*
- Graves' disease, 185
- grief, in terminally ill patients, 228, 229*t*
- Groves, J.E., 26–7, 28, 29
- guarded-suspicious personality type, 24*t*
- Gurwith, M., 83–4
- hallucinations  
by AIDS patients, 166–7, 168*t*  
in Parkinson's disease, 121
- haloperidol, 33*t*, 47  
combined with lorazepam, 61  
controlling agitated patients with, 60–1  
for patients with delirium, 68, 69  
for terminally ill patients, 231*t*, 232
- Hamilton, J.C., 87
- hand mitts, 70
- Hashimoto's encephalopathy (chronic autoimmune thyroiditis), 185, 190
- Hashimoto's thyroiditis, 184, 190
- "hateful" patients, 26–7, 27*t*, 27, 30*t*
- head injury. *See* traumatic brain injury (TBI)
- healthcare providers, role in perinatal depression care, 206
- heart disease  
depression and, 100–5  
background, 100–1  
clinical decision-making and treatment, 102–5  
consult question, 100  
screening and assessment, 102  
work-up, 102
- in end-stage renal disease (ESRD), 178
- helplessness, 26–7, 236–7
- hemodialysis (HD), 175
- hepatic encephalopathy, 212, 213
- hepatitis C, depression and  
background, 153–5  
clinical decision-making and treatment  
consult question, 153  
future directions, 160  
overview, 153  
screening and assessment, 155
- high arousal states, 60
- high dopaminergic tone, delirium, 65
- histamine receptor antagonism, 188
- histrionic patients, 27
- HMG-CoA reductase inhibitors, 105
- hopelessness, 53, 236–7
- hospice  
background, 226–8  
clinical decision-making and treatment, 230–3  
consult question, 226  
work-up, 228–30
- hospitalized, medically ill patients  
background, 242  
consult question, 242  
stress factor of hospitalization, 22–3  
work-up
- hostile dependents, 28
- House, A., 75
- human immunodeficiency virus (HIV), 48. *See also* AIDS
- Huntington's disease (HD), 91  
agitation in, 96  
medications for, 96
- hydromorphone, 69
- hypercalcemia  
diagnosis of, 190  
and hyperparathyroidism, 186  
and hypoparathyroidism, 186
- hypercortisolism, 186–7
- hyperglycemia, 188
- hyperparathyroidism, 186
- hyperprolactinemia, 189–90
- hyperthyroidism, 185
- hypnotic withdrawal, 196
- hypnotics  
and interferon-induced depression, 158*t*  
and organ transplant patients, 213
- hypoactive delirium, in AIDS patients, 165, 170
- hypoalbuminemia, 40
- hypochondriasis, 76–7  
background, 76  
clinical decision-making and treatment, 76–7
- hypocortisolism, 187
- hypomania, 120, 187
- hypoparathyroidism, 186
- hypothyroidism, 184–5  
and cardiac function, 102  
lithium and, 41
- hysterical symptoms. *See* somatoform disorder
- I WATCH DEATH mnemonic, 67*t*
- ICAM-1 (intercellular adhesion molecule 1), 156*t*, 157
- ictal symptoms of epilepsy, 136–7
- idealization, in dependent clingers, 27
- IFN therapy, 157–60
- ill-defined confusion, 6
- illness narratives, 243–4
- imaging, 5–6
- imipramine, 33*t*



Index

- immature defense
  - mechanisms, 25, 25*t*, 25
- immunosuppressive
  - medications, 214
- impulse control disorders (ICDs), 123
- inborn traits, 23
- incompetence, subjective, 236–7
- The Indiana Cyclone
- informed consent, 15, 17–18
- insomnia
  - in cancer patients, 146–7
  - in interferon-induced depression, 158, 159–60
  - in Parkinson's disease, 122–3
  - in terminally ill patients, 230
- interferon-induced depression, 153–60
  - background, 153–5
  - clinical decision-making and treatment,
  - consult question, 153
  - future directions, 160
  - guidelines for treatment of, 159*t*
  - hepatitis C and depression, 155–7
  - neuropsychiatric
    - complications of,
    - medications used for, 158*t*
  - overview, 153
  - proposed mechanisms for, 156*t*
  - psychiatric consultation
    - prior to therapy, 154*t*
  - screening and assessment, 155
- interictal dysphoric disorder, 137
- interictal symptoms of
  - epilepsy, 135, 136–7
- interpersonal difficulties, 244
- Interpersonal Psychotherapy (IPT), 204
- interpretive services, 8
- interventions, 9–12
  - ancillary resources, 11
- communicating directly with
  - consulting team, 12
- laboratory studies, 11
- non-pharmacologic
  - interventions, 11
- notes, 9
- offering treatment
  - recommendations, 9
- pharmacologic
  - interventions, 11
- returning for follow-up visits
  - and recommendations, 12
- safety, 9–11
- interview, consultation, 10*t*
- intramuscular olanzapine, 62, 63
- intramuscular ziprasidone, 62, 63
- involuntary commitment, 17
- irritability, in people with
  - epilepsy (PWE), 136
- isocarboxazid, 33*t*
- Jacobsen, P.B., 146
- Janet, P., 74
- Jorge, R.E.,
- juvenile myoclonic epilepsy (JME), 135
- Kalarchian, M.A., 218
- Kanaan, R., 75
- Kimmel, P.L., 175
- Kinder, B.N., 221
- Konovalov, S., 95
- Kraepelin, E., 137
- laboratory studies
  - recommending, 11
  - results of, 5–6
- lactation, antidepressants and, 205
- lactulose, 213
- lamotrigine, 33*t*, 40
  - for people with epilepsy (PWE), 140
  - for perinatal psychosis, 205
- Langston, C., 83–4
- lansoprazole, 38*t*
- levetiracetam
  - for people with epilepsy (PWE), 140
  - and seizure disorders, 137
- Lewy Body dementia (DLB), 91
- light therapy, 205
- limb restraints, 70
- linezolid, 38*t*
- Lipsey, J.R., 111*t*
- lithium, 40–1, 185
  - for hyperparathyroidism, 186
  - for people with epilepsy (PWE), 139, 140
  - for perinatal psychosis, 206
- lofexidine, 200
- Loftis, J.M., 155
- lorazepam, 33*t*
  - for alcohol withdrawal, 196*t*
  - for interferon-induced depression, 160
  - for terminally ill patients, 231*t*, 230–2
- low cholinergic tone, delirium, 65
- Loxitane, 139
- lucidity, confirming before
  - altering medication, 69
- maladaptive denial, 18
- Maldonado, J., 212
- malingering, 82–8
  - background, 82–5
  - clinical decision-making and treatment, 86–8
  - consult question, 82
  - work-up, 85
- mania, 120
  - in interferon-induced depression, 160
  - in Parkinson's disease patients, 120
  - in people with epilepsy (PWE), 136
- manipulative help-rejecters, 28
- maprotiline, 139

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- masochistic personality type, 24*t*, 28
- massage, for dementia and agitation, 94
- mature defense mechanisms, 25*t*
- McCoy, J.P., 148
- medical records, 4–5
- medically ill patients  
  assessing capacity in, 15–20  
  background, 15–18  
  clinical decision-making and treatment, 19–20  
  consult question, 15  
  work-up, 18–19
- hospitalized,  
  background, 242  
  consult question, 242  
  work-up,  
  psychopharmacology in, 32–49  
  classes of medications, 39–44  
  developing approach to, 32  
  overview, 32  
  pharmacodynamics, 37–9  
  pharmacokinetics, 37–9
- medically unexplained symptoms (MUSs). *See* somatoform disorder
- medical-psychiatry units (MPUs), 55
- Medicare hospice benefit, 227
- melanoma, 157
- memantine, 96
- Memorial Delirium Assessment Scale, 67
- mental flexibility, consultant, 3
- mental status examination, 8*t*
- meperidine, 38*t*, 69
- metabolism, 37
- methadone, 172, 197–8, 199*t*, 199, 199*t*, 199
- methimazole, 191
- methylphenidate, 48  
  for end-stage renal disease (ESRD), 181  
  for post-stroke depression, 110  
  for terminally ill patients, 230, 231*t*  
  for traumatic brain injury patients, 131
- metoclopramide, 228
- midazolam, 33*t*, 232
- mild toxicity, lithium, 41
- Millon Behavioral Medicine Diagnostic (MBMD), 221
- Mini-Mental State Examination (MMSE), 19, 66–7, 122
- Minnesota Multi-Phasic Personality Inventory, 2nd edition (MMPI-2), 85
- mirtazapine, 33*t*  
  for cancer patients, 147  
  for depression, 44  
  interferon-induced, 158, 160  
  in patients with heart disease, 103  
  perinatal, 205  
  for end-stage renal disease (ESRD) patients, 180*t*, 180  
  for terminally ill patients, 230, 231*t*  
  for traumatic brain injury patients, 131
- mistrust, effect on decision making ability, 20
- mixed dementias, 91
- moclobemide, 33*t*
- modafinil, 48–9, 159
- Modified Somatic Perception Questionnaire, 85
- Molitch, M.E., 190
- monoamine oxidase inhibitors (MAOIs), 41–2
- for depressed patients with heart disease, contraindications, 103–4  
  for end-stage renal disease (ESRD) patients, 179, 181  
  and perinatal depression patients, 205  
  and prolactin, 189  
  for traumatic brain injury patients, contraindications, 131
- mood disorders, 119
- mood stabilizers, 40  
  for children, 255*t*  
  cited problems with, 30  
  and interferon-induced depression, 158*t*  
  pregnancy and depression, 205–6
- morale. *See* demoralization
- Morris, P.L.P., 107
- MorVAST model, 148
- multidisciplinary healthcare teams, 4
- Munchausen by proxy, 250
- Munchausen's syndrome, 82–8  
  background, 82–5  
  clinical decision-making and treatment, 86–8  
  consult question, 82  
  work-up, 85
- Murray, V., 111*t*
- music therapy, 11, 94
- Mycobacterium avium intracellulare* (MAC) retinitis, 166–7
- myoclonic seizures, 135
- narcissistic patients, 27–8
- narcotics, 11
- narratives, illness, 243–4
- National Comprehensive Cancer Network (NCCN), 144, 148

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- needy-clingy personality type, 24*t*
- nefazodone, 33*t*  
for depressed patients with heart disease, 103  
for depression, 43  
interaction with medications for CVD, 104*t*, 104, 104*t*, 104  
for perinatal depression, 205
- neonatal toxicity, 206
- neuroleptic drugs, 228
- neuroleptic malignant syndrome (NMS), 46
- neuroleptics, 232
- neurologic examinations, 8
- neuropsychological testing, 19
- neurotic defense mechanisms, 25*t*, 25–6
- neurotransmitter states, delirium, 65
- nicotine, 38*t*
- Night Eating Questionnaire (NEQ), 222
- night eating syndrome (NES), 218
- N*-methyl-*D*-aspartate (NMDA) receptors, 157
- no-harm contracts, 55–6
- non-benzodiazepine sedative/hypnotic medications, 45, 159–60
- non-epileptic seizures (NES), 75
- non-pharmacological therapies for cancer and depression overview, 11  
for pregnancy and depression, 204  
for renal failure and depression, 181
- non-psychiatric services, 11
- non-steroidal anti-inflammatory drugs, 41
- norepinephrine transporter (NET), inhibitors of, 48
- normalization, suicide risk assessment, 54
- nortriptyline, 33*t*  
for depressed patients with heart disease, contraindications, 103  
for infants of breastfeeding mothers, 205  
for poststroke depression, 110  
for terminally ill patients, 231*t*
- no-suicide contracts, 55–6
- notes, 4, 9
- nursing notes, 19
- nutrition, for cancer and depression, 148
- obesity, 188–9. *See also* appetite, psychostimulants and; bariatric surgery; eating disorders; weight problems
- obsessive-compulsive disorder (OCD), 77, 120
- obstructive sleep apnea (OSA), 122–3
- occupational therapy (OT), 6, 130
- odd patient personality type, 24*t*
- O*-desmethyl-venlafaxine, 179–80
- “off label” antipsychotics, 48
- olanzapine, 33*t*, 48, 95  
for dementia and agitation, 94  
for Parkinson’s disease, contraindications, 121  
for terminally ill patients, 231*t*  
treating acute agitation with, 62  
and weight gain, 188
- omega-3 fatty acids, for perinatal depression, 205
- omeprazole, 38*t*
- open-ended questions, 54  
with agitated patients, 60  
competency/capacity interview, 19
- opioid agonist therapy (OAT), 196–8, 199
- opioid analgesics  
for children, 256  
for terminally ill patients, 232
- opioid withdrawal, 196  
sample withdrawal protocols, 199*t*  
signs and symptoms of, 197*t*
- orderly-controlled personality type, 24*t*
- organ transplantation  
background, 210–11  
clinical decision-making and treatment  
peri-operative period, 214  
post-transplant period, 214  
pre-transplant period, 213  
consult question, 210  
psychosocial rating scales, 212  
work-up
- organization, institutional and personal, 1
- Organization of AIDS Psychiatry (OAP), 165
- osmotic diuretics, 41
- overt hypothyroidism, 184
- oxazepam, 33*t*, 160
- oxcarbazepine, 33*t*, 40, 140
- pain disorder, 78  
background, 78  
clinical decision-making and treatment, 78  
work-up, 78
- pain medications, and organ transplant patients, 213
- paliperidone, 33*t*
- palliative medicine  
background, 226–8

## Index

- palliative medicine (*cont.*)  
 clinical decision-making and treatment, 230–3  
 consult question, 226  
 definition of palliative care, 227  
 work-up, 228–30
- parathyroid hormone (PTH), 186
- parathyroidectomy, 191
- Parkinson's disease (PD), 91, 116–24  
 background, 116, 117–18  
 clinical decision-making and treatment, 117, 118  
 consult question, 116  
 specific psychiatric disorders in, 119–24  
 anxiety disorders, 120  
 behavioral changes, 123  
 clinical decision-making and treatment, 119–21  
 cognitive disorders, 121–2  
 delirium, 122  
 dopaminergic medication abuse, 123–4  
 impulse control disorders, 123  
 mood disorders, 119  
 psychotic disorders, 121  
 sexual disorders, 123  
 sleep disorders, 122–3  
 work-up, 119, 120, 121, 122
- work-up, 116–17, 118
- paroxetine, 33*t*  
 for cancer patients, 147  
 for end-stage renal disease (ESRD), 179, 180*t*  
 for infants of breastfeeding mothers, 205  
 interaction with medications for CVD, 104*t*, 104, 104*t*, 104  
 for interferon-induced depression, 157
- partial seizures, defined, 134
- passive-aggression, in dependent clingers, 27
- pastoral care, for cancer patients, 148
- Patel, 219
- patient appraisals and illness narratives, 243–4
- patient autonomy, 15
- patient capacity, 3
- Patient Health Questionnaire (PHQ-9), 243
- patients. *See also* patients, difficult  
 examining, 8  
 identity of, 2  
 interviewing, 6  
 location of, 2
- patients, difficult, 22–31  
 background, 22–3  
 clinical decision-making and treatment, 29–31  
 behavioral management, 29–30  
 psychopharmacology, 30–1  
 consult question, 22  
 violent patients, 58–63  
 background, 58–9  
 clinical decision-making and treatment, 60  
 psychopharmacologic management of agitated, violent patient, 60–3  
 typical consult question, 58  
 work-up, 59–60
- work-up, 23–9  
 coping styles, 23–4  
 countertransference, 26  
 defense mechanisms, 25–6  
 dependent clingers, 27  
 entitled demanders, 27–8  
 “hateful” patients, 26–7  
 manipulative help-rejecters, 28  
 overview, 23  
 personality types, 23  
 self-destructive deniers, 29
- pegylated interferon-alpha, 153–60
- perinatal depression. *See* pregnancy, depression and
- peritoneal dialysis (PD), 175
- persistent pulmonary hypertension of the newborn (PPHN), 205
- personality disorders (PD), 23  
 incidence in cancer patients, 143  
 in obese people, 217
- personality types, 23
- pet therapy, 11
- pharmacodynamics, 37–9
- pharmacokinetics, 37–9
- pharmacological parsimony, 32
- pharmacology, 11
- phenelzine, 33*t*
- phenobarbital  
 for people with epilepsy (PWE), 140  
 for seizure disorders, contraindications, 137
- phenytoin  
 drug-drug interactions, 38*t*  
 for people with epilepsy (PWE), 140  
 for seizure disorders, contraindications, 137
- Phillips, K.A., 77
- physical examinations, 8
- physical therapy (PT), 6, 75
- physician beneficence, 15
- playful problem solving, 24*t*
- poor coping, 24
- positive reappraisal, 24*t*
- post-ictal psychosis, 136
- post-ictal symptoms of epilepsy, 135, 136–7
- post-partum depression. *See* pregnancy, depression and
- post-stroke depression, 107–13  
 assessment and treatment protocol for, 110*t*  
 background, 107–9  
 clinical decision making and treatment, 109–11  
 consult question, 107  
 differential diagnosis for, 108*t*

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- effect of antidepressants on
  - outcome, 112
  - mortality, 112
  - recovery in activities of daily living, 112
  - recovery in cognitive function, 112
- preventive intervention, 113
- psychosocial interventions, 112–13
- treatment studies of, 111*t*
- work-up, 109
- post-traumatic brain injury
  - depression. *See* traumatic brain injury (TBI), depression and
- post-traumatic stress disorder (PTSD), 164–5, 170
- power struggles, 20
- pramipexole, 120
- prednisone, 214
- pregabalin, 33*t*, 39, 40, 140
- pregnancy
  - alcohol and other substance withdrawal issues, 200
  - antiepileptic drug (AED) use during, 138–9
  - and bariatric surgery, 219
  - depression and,
    - background, clinical decision-making and treatment, consult question, 202
    - work-up, 203
- preictal symptoms of epilepsy, 135, 136–7
- primary hyperparathyroidism, 191
- primary hypothyroidism, 184
- primary team, communication with, 12
- primidone
  - for people with epilepsy (PWE), 140
  - for seizure disorders, contraindications, 137
- problem-focused coping, 23
- pro-inflammatory cytokines, 155–7
- prolactin, elevated, 189–90
- prolactinomas, 189–90
- prophylactic medications, 157
- propylthiouracil, 191
- protease inhibitors, 38*t*
- protective factors, suicide, 53
- protriptyline, 33*t*
- pseudobulbar affect in
  - Parkinson's disease, 119
- psychiatric disorders
  - in agitated patients, 59
  - in cancer patients, 143
  - in hepatitis C patients, 154
  - in Parkinson's disease, contraindications, 117–18
  - in people with epilepsy (PWE), 135
  - in terminally ill patients, 231*t*
- psychogenic nonepileptic events, 136
- psychooncology. *See* cancer, depression and
- psychopharmacology, 32–49
  - classes of medications, 39–44
    - anticonvulsants, 39–40
    - antidepressants, 41–4
    - antipsychotics, 45–6, 47–8
    - anxiolytics and sedatives, 44–5
    - lithium, 40–1
    - mood stabilizers, 40
    - neuroleptic malignant syndrome (NMS), 46
    - psychostimulants, 48–9
    - QTc prolongation, 46–7
    - serotonergic syndrome, 43
    - torsades de pointes (TdP) ventricular arrhythmia, 46–7
  - developing approach to, 32
  - difficult patients, 30–1
  - overview, 32
  - pharmacodynamics, 37–9
  - pharmacokinetics, 37–9
  - violent patients, 60–3
- psychosis
  - effect on decision making ability, 20
  - perinatal, 205–6
  - and postpartum depression, 203
- Psychosocial Assessment of Candidates for Transplantation (PACT), 212
- psychostimulants, 48–9
  - for end-stage renal disease (ESRD) patients, 181
  - for interferon-induced depression, 159
  - for terminally ill patients, 230
  - for traumatic brain injury patients, 131
- psychotherapy
  - for cancer patients, 147–8
  - for hospitalized, medically ill patients
    - background, 242
    - consult question, 242
    - work-up
  - for major depression in CVD, 104
  - for Parkinson's disease, 120
  - for terminally ill patients, 232
- psychotic defense mechanisms, 25*t*
- psychotic disorders, 121
- psychotropic drugs, 30
  - for people with epilepsy (PWE), 139–40
  - for perinatal depression, 204
  - pharmacokinetics, 33*t*
  - volume of distribution, 37
- QTc prolongation, 45–7
- quetiapine, 33*t*, 48, 95, 172
- Rackley, S.J., 52
- ramelteon, 33*t*, 45
- Rampello, L., 111*t*
- rapid tranquilization, 61
- rash, from antiepileptic drugs (AEDs), 139

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- Rea, J.D., 217
- reboxetine, 103
- recent orders, 5
- reciprocal interaction, 56
- records, medical, 4–5
- Reding, M.J., 111*t*
- refractory agitation, 39
- refusing treatment, 16
- relaxation therapy, 11, 105
- religion, and cancer patients, 148
- REM behavior disorder (RBD), 122–3
- renal failure  
  depression and  
    antidepressant medication  
    therapy, 179–81  
  background  
  clinical decision-making  
  and treatment  
  consult question, 174  
  work-up  
  types and epidemiology of  
  renal disease, 174
- renal replacement therapies, 175
- repolarization delay  
  (QT-interval  
  prolongation), 199
- reversible inhibitor of MAO-A  
  (RIMA), 33*t*
- ribavirin, 153–60
- rifampin, 38*t*
- rifaximin, 213
- risk versus benefit analysis, 16
- risperidone, 33*t*, 47, 94, 95, 121
- rivastigmine, 96
- Robinson, R.G., 107, 111*t*
- role transitions, 244
- routine consults, 3
- Rubin, 78
- Rudd, M.D., 52–4, 55–6
- Ruddy, J.J., 75
- Ruiz, P., 165
- Rundell, J.R., 1
- safety, 9–11
- Sallet, P.C., 218
- SARI trazodone, 43
- schizophrenia  
  and hypothyroidism, 191  
  in terminally ill patients,  
  226  
  and weight problems, 188
- Schneider, L.S., 94
- secondary hypothyroidism, 184
- sedatives, 44–5. *See also*  
  benzodiazepines  
  buspirone, 45  
  non-benzodiazepine  
  sedative/hypnotic  
  medications, 45  
  withdrawal from, 196
- seeking social support coping  
  style, 24*t*
- seizure disorders  
  background  
  definitions and  
  classification, 134–5  
  epidemiology, 135–6  
  clinical decision-making and  
  treatment  
  epilepsy treatment, 138–9  
  overview, 138  
  psychiatric disorder  
  treatment, 139–40  
  consult question, 134  
  work-up  
  AEDs, 137  
  epilepsy, 136–7  
  neuropsychological  
  testing, 138  
  overview, 136  
  seizures, 136  
  suicide risk assessment,  
  137–8
- selective serotonin reuptake  
  inhibitors (SSRIs), 42–3  
  for anxiety in Parkinson's  
  disease, 120–1  
  for body dysmorphic  
  disorder, 78  
  for depressed patients with  
  heart disease, 101,  
  102–3  
  for diabetes, 191  
  for end-stage renal disease  
  (ESRD) patients, 179
- for interferon-induced  
  depression, 157–8  
  for organ transplant  
  patients, 213  
  for Parkinson's disease  
  patients, 119  
  for people with epilepsy  
  (PWE), 139  
  for perinatal depression,  
  204–5  
  for post-stroke depression,  
  110  
  and prolactin, 189  
  for terminally ill patients,  
  230  
  for traumatic brain injury  
  patients, 131
- selegiline, 120
- self-controlling coping style,  
  24*t*
- self-destructive deniers, 29
- self-image, of terminally ill  
  patients, 228
- serotonergic syndrome, 43
- serotonin 2C (5-HT<sub>2C</sub>)  
  receptors, 188
- serotonin, and  
  interferon-induced  
  depression, 156*t*, 156,  
  158*t*
- serotonin reuptake inhibitors  
  (SSRIs)  
  and interferon-induced  
  depression, 158*t*  
  for perinatal depression, 204
- serotonin-norepinephrine  
  reuptake inhibitors  
  (SNRIs), 42–3  
  for depressed patients with  
  heart disease, 103  
  for depressed patients with  
  hepatitis C, 158  
  for end-stage renal disease  
  (ESRD) patients,  
  179–80  
  and interferon-induced  
  depression, 158*t*  
  for Parkinson's disease  
  patients, 119–20  
  for perinatal depression, 205  
  for traumatic brain injury  
  patients, 131



Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- sertraline, 33*t*  
   for depressed patients with heart disease, 102  
   for end-stage renal disease (ESRD), 180*t*  
   for infants of breastfeeding mothers, 205  
   interaction with medications for CVD, 104  
   for interferon-induced depression, 158  
   for terminally ill patients, 230, 231*t*  
   for traumatic brain injury patients, 131
- serum calcium, and hyperparathyroidism, 186
- serum HDL cholesterol, 188
- serum triglycerides, 188
- sexual abuse  
   bariatric history of, 218  
   and pain disorder, 78
- sexual disorders, 123
- shame attenuation, 54
- Shapiro, A.P., 86, 87
- Shea, S.C., 52
- Silecchia, G., 217
- Skalla, K., 148
- Slavney, P., 235
- sleep disturbances, 122–3  
   in cancer patients, 146–7  
   in patients with interferon-induced depression, 158, 159–60
- somatization disorder, 74  
   background, 74  
   clinical decision-making and treatment, 74  
   work-up, 74
- somatoform disorder, 73–8  
   background, 73  
   body dysmorphic disorder, 77–8  
   background, 77  
   clinical decision-making and treatment, 77–8  
   work-up, 77  
   consult question, 73
- conversion disorder, 74–6  
   background, 74–5  
   clinical decision-making and treatment, 75–6  
   work-up, 75
- hypochondriasis, 76–7  
   background, 76  
   clinical decision-making and treatment, 76–7
- pain disorder, 78  
   background, 78  
   clinical decision-making and treatment, 78  
   work-up, 78
- somatization disorder, 74  
   background, 74  
   clinical decision-making and treatment, 74  
   work-up, 74
- spiritual care, for cancer and depression, 148
- St. John's Wort, 179
- Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT), 212
- statins, 105
- Stevens Johnson syndrome (SJS), 40, 139
- stimulants  
   for children, 255*t*  
   for interferon-induced depression, contraindications, 158*t*  
   for people with epilepsy (PWE), 139  
   for post-stroke depression, 110
- stress  
   caused by medical illness and hospitalization, 22–3  
   as suicide risk factor, 53
- stroke, 104*t*. *See also* post-stroke depression
- subclinical hypothyroidism, 184, 185
- subcortical dementias, 90*t*, 91  
   Huntington's disease, 91  
   Parkinson's disease, 91
- subjective incompetence, 236–7
- substance abuse. *See also* alcohol and other substance withdrawal issues  
   and organ transplant patients, 213  
   and renal failure, 177  
   suicide risk factor, 52  
   in terminally ill patients, 226–7, 228–30, 232
- suicide. *See also* suicide risk assessment  
   in AIDS patients, 164, 168–9  
   in end-stage renal disease (ESRD) patients, 177  
   following traumatic brain injury, and patients in treatment for HCV, 155  
   and perinatal depression, 203
- suicide risk assessment, 51–6  
   background, 51–2  
   clinical decision-making and treatment, 55–6  
   consult question, 51  
   seizure disorders, 137–8  
   work-up, 52–5  
   behavioral incident, 54  
   denial of the specific, 54  
   gentle assumption, 54–5  
   normalization, 54  
   overview, 52–4  
   shame attenuation, 54  
   symptom amplification, 55
- superior-critical personality type, 24*t*
- supplements, for cancer and depression, 148
- swallow studies, 6
- Sydenham, T., 74
- symptom amplification, 55
- symptomatic detoxification, 199–200
- tacrolimus  
   drug-drug interactions, 38*t*  
   for organ transplant patients, 214

Cambridge University Press

978-0-521-10665-8 - Psychosomatic Medicine: An Introduction to Consultation-Liaison Psychiatry

Edited by James J. Amos and Robert G. Robinson

Index

[More information](#)

## Index

- tamoxifen, 147
- Teasell, R.W., 86, 87
- teenagers. *See* children
- temazepam, 33*t*, 160
- temperament, 23
- terminally ill patients, 250. *See also* end of life, psychiatric care at
- tertiary hypothyroidism, 184
- Test of Malingered Memory (TOMM), 85
- thiamine, 195
- thiazide diuretics, 41
- thin-slicing, 58
- thyroid storm, 191
- tiagabine  
for people with epilepsy (PWE), 140  
for seizure disorders, contraindications, 137
- timid-apprehensive personality type, 24*t*
- tonic-clonic seizures, 134
- topiramate, 33*t*, 40  
for people with epilepsy (PWE), 140  
for seizure disorders, contraindications, 137
- torsades de pointes (TdP)  
ventricular arrhythmia, 45–7
- torso restraints, 70
- toxic epidermal necrolysis, 139
- toxicity, lithium, 41
- tramadol, 38*t*
- tranquilization, 61
- Transplant Evaluation Rating Scale (TERS), 212
- transplantation. *See* organ transplantation
- tranylcypromine, 33*t*, 42
- traumatic brain injury (TBI), 92  
agitation in, 96
- aspects of diagnostic evaluation, 129*t*
- depression and  
background  
clinical decision-making and treatment,  
consult question, 126  
work-up, 128–30
- direct/indirect physiological effect of, 127*t*
- medications for, 96
- trazodone, 33*t*  
for interferon-induced depression, 160  
for perinatal depression, 205
- triazolam, 33*t*
- tricyclic antidepressants (TCAs), 33*t*, 41–2  
for depressed patients with heart disease, contraindications, 103  
for end-stage renal disease (ESRD) patients, 179, 180  
for Parkinson's disease patients, 119–20  
for perinatal depression, 205  
for traumatic brain injury patients, contraindications, 131
- trimipramine, 33*t*
- tryptophan, 156
- Tsuda, S., 217
- Turner, M.A., 83
- UDP-glucuronosyltransferase (UGT) 1A4, 40
- UIHC Pharmacy and Therapeutics (P & T) Subcommittee, 62
- understanding, as aid to developing empathy, 29
- unprovoked seizures, 135
- uremia, 176, 177
- urgent consults, 3
- valproate  
for delirium, 69
- for perinatal psychosis, 205
- valproic acid, 33*t*, 39–40  
for people with epilepsy (PWE), 140  
risks factors, 138  
and seizure disorders, 137
- vascular dementia (VaD), 91
- venlafaxine, 33*t*  
for cancer patients, 147  
for depressed patients with heart disease, 103  
for depression, 42  
for end-stage renal disease (ESRD) patients, 180*t*, 179–80, 180*t*, 180  
for perinatal depression, 205  
for traumatic brain injury patients, 131
- Veterans Administration (VA), suicide prevention campaign, 52
- vigabatrin, 137
- violent patients, 58–63  
background, 58–9  
clinical decision-making and treatment, 60  
psychopharmacologic management of, 60–3  
typical consult question, 58  
work-up, 59–60
- visual hallucinations, 121
- vital signs, 5
- vulnerable child syndrome, 251*t*
- Wadden, T.A., 220
- warfarin, 38*t*
- Ways of Coping Questionnaire-Revised, 24
- weight problems, 188–9. *See also* appetite, psychostimulants and; bariatric surgery; eating disorders
- Wellen, M., 102
- Wernicke-Korsakoff syndrome, 195

Index

WHHHIMP mnemonic, 67 <i>t</i>	xanthines, 41	zonisamide, 140
Wiat, L., 111 <i>t</i>	Yudofsky, S.C., 92	zopiclone, 33 <i>t</i>
Wise, M.G., 1		for insomnia, 45
Wise, T., 102		for interferon-induced depression, 159–60
Wong-Baker Faces, 256		Zung Self-Rating Depression Scale or Center for Epidemiologic Studies Depression Scale (CES-D), 155
World Health Organization Quality of Life (WHOQOL-BREF), 222	zaleplon, 33 <i>t</i> , 45	
	ziprasidone, 33 <i>t</i> , 62, 191	
	zolpidem, 33 <i>t</i>	
	for insomnia, 45	
	for interferon-induced depression, 159–60	